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ABSTRACT: Chagas disease is responsible for 12 thousand 
deaths annually in the Americas, mainly due to Chronic Chagas 
Cardiomyopathy (CCC) that occurs in 20 to 30% of those infected 
people, after 60 years old, 30 to 40 years after the first infection, 
leading to biventricular heart failure (HF), arrhythmias, blocks 
and embolisms. The diagnosis is based on epidemiology, clinical 
condition, electrocardiographic changes and imaging tests 
associated with serology. The present study reports the case of a 
patient with atypical evolution for her age due to rapid progression 
to advanced and refractory HF, associated with high morbidity and 
mortality, a typically late manifestation of CCC. Clinical case: 37 
years old female patient admitted to the Intensive Care Unit of a 
tertiary hospital in a city of São Paulo State for decompensated 
congestive heart failure, associated with pleural effusion. The 
echocardiogram and serology for Trypanosoma Cruzi confirmed 
the diagnosis of CCC and risk of mortality estimated in 84%. 
Treatment started with beta-blocker, spironolactone, diuretic, 
enalapril and patient was discharged from hospital. After 20 
months, she was readmitted with cardiogenic shock, cardio-renal 
syndrome and atrial fibrillation treated with diuretics, inotropic 
and amiodarone, and progressing to death after three days. It 
was not possible to refer for resynchronization therapy or heart 
transplantation, due to psychiatric comorbidity, poor medication 
adherence and unavailability at the service. The precocious 
presentation of advanced and refractory HF, in this case, revels 
the importance of adherence to medication treatment, reduction 
of readmissions and the quick referral to a transplant center and 
ventricular support, in an attempt to reduce the morbidity and 
mortality of these patients. 
Keywords: Chagas Cardiomyopathy; Chagas disease; Heart 
Failure.
RESUMO: A Doença de Chagas é responsável por 12 mil mortes 
anualmente nas Américas em decorrência da Cardiomiopatia 
Chagásica crônica (CCC) que ocorre em 20 a 30% dos infectados, 
após os 60 anos, 30 a 40 anos após a primo-infecção, levando 
à Insuficiência Cardíaca (IC) biventricular, arritmias, bloqueios 
e embolias. O diagnóstico é baseado na epidemiologia, quadro 
clínico, alterações eletrocardiográficas e de exames de imagem 
associados à sorologia. O presente estudo relata o caso de paciente 
com evolução atípica para a idade devido à rápida progressão 
para IC avançada e refratária, associada à alta morbimortalidade, 
manifestação tipicamente tardia da CCC. Caso clínico: paciente 
de 37 anos, sexo feminino, internada na Unidade de Terapia 
Intensiva de um hospital terciário no interior do Estado de São 
Paulo por IC congestiva descompensada, associada a derrame 
pleural. O ecocardiograma e sorologia para Trypanossoma 
Cruzi confirmaram o diagnóstico de CCC e risco de mortalidade 
estimado em 84%. Foi iniciado tratamento com betabloqueador, 
espironolactona, diurético, enalapril e paciente recebeu alta. 
Após 20 meses, reinternou com choque cardiogênico, síndrome 
cardiorrenal e fibrilação atrial tratados com diuréticos, inotrópicos 
e amiodarona, evoluindo para óbito após três dias. Não foi possível 
encaminhamento para terapia de ressincronização ou transplante 
cardíaco, devido à comorbidade psiquiátrica, má adesão 
medicamentosa e indisponibilidade no serviço. A precocidade 
da apresentação da IC avançada e refratária, neste caso, 
revela a importância da adesão ao tratamento medicamentoso, 
redução de reinternações e o rápido referenciamento a centro de 
transplante e suporte ventricular, como tentativa de diminuir a 
morbimortalidade desses pacientes. 
Palavras-chave: Cardiomiopatia chagásica; Doença de Chagas; 
Insuficiência Cardíaca.
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INTRODUCTION
Chagas disease is the third most prevalent parasitic disease, caused by Trypanossoma 
Cruzi (T. Cruzi), prevailing in Latin America1-3. The most 
recent estimates in Brazil regarding the number of people 
infected range from 1.9 to 4.6 million people, about 1.0 to 
2.4% of the population4.
Among patients infected with T. Cruzi, only 20% to 
30% develop Chronic Chagasic Cardiomyopathy (CCC), 
which is the most serious condition of Chagas disease 
and usually occurs decades after the initial infection5. 
Chagas disease in its chronic form, in a habitual way, 
initially presents with no symptoms or alterations in 
the electrocardiogram or chest x-ray characterizing the 
Indeterminate Form, which can generally last from 30 
to 40 years. After this period, patients can develop to the 
Determinate Form, without symptoms, with alterations in 
the exams, however, without ventricular dysfunction (B1) 
or with ventricular dysfunction (B2). Then, they develop 
to ventricular dysfunction and symptoms (C) and, finally, 
to the form with ventricular dysfunction and refractory 
symptoms (D)6. The typical evolution of this last phase is 
dilated cardiomyopathy, with bi-ventricular heart failure, 
and there may be a predominance of symptoms related to 
the involvement of the right ventricle, such as jugular stasis, 
hepatomegaly, ascites and lower limb edema. As symptoms, 
we can mention asthenia, dyspnea and atypical angina. 
The main complications involve ventricular arrhythmias, 
conduction disorders, abnormalities of the microcirculation, 
stroke and other systemic embolic events7,8.
The report aims to describe the case of a young 
patient with Chagas Disease with severe and early 
cardiac manifestations and to analyze its evolution and 
complications, suggesting a form with faster evolution in 
young patients. This report was approved by the Research 
Ethics Committee (REC) of Fundação Santa Casa de 
Misericórdia de Franca, SP, Brazil with CAAE number 
860662218.0.0000.5438 with previous collection of the 
Informed Consent Form (ICF). The information contained 
in the report was obtained through interviews with the 
patient and review of electronic medical records, and the 
reported tests were carried out in a tertiary hospital in 
Santa Casa de Franca and Hospital do Coração, a regional 
reference for patients with heart failure.
CASE REPORT
CRC, female, 37 years old, resident and coming 
from São Paulo State and born in an endemic area of Chagas 
Disease in Brazil She was admitted to the Intensive Care 
Unit of Hospital do Coração de Franca – SP - Brazil, a 
tertiary hospital specialized in cardiological pathologies, 
being a reference in advanced heart failure in the region, in 
September 2017. She presented symptoms, which started 
four months before admission, of class III congestive heart 
failure according to the classification of New York Heart 
Association (NYHA)9, without previous history of heart 
disease. At the time, IgG serology was requested for T. Cruzi, 
using the chemiluminescence and immunofluorescence 
method, which confirmed the diagnosis, with a value of 
1/120. No serology was performed for IgM anti T. Cruzi, 
quantitative PCR and search for parasite in peripheral blood 
due to the unavailability of these tests at the service, and it 
is not possible to make a definitive diagnosis according to 
the criteria established by the World Health Organization 
and the current guidelines10. However, the patient had no 
fever in the last 60 days before admission and the clinical 
epidemiological criterion for the management of the case 
was considered as CCC in the Determined Form C. Despite 
the patient’s origin, it was not possible to accurately identify 
the period in which the patient was contaminated because, 
on the date of the interview, the patient was unable to 
provide more specific information, however, we can infer 
that it occurred possibly between five and ten years before 
admission.
The echocardiogram made during hospitalization 
showed a left ventricular ejection fraction of 23%, with a 
diastolic diameter of the right ventricle of 67 mm, systolic 
pressure of pulmonary artery of 46 mmHg, enlargement 
of left and right cavities, with mild pericardial effusion, 
significant diffuse hypokinesia of left ventricle and right 
ventricle, mild to moderate mitral regurgitation and 
pulmonary arterial hypertension (Figures 1 and 2).
After starting treatment with beta-blockers, 
spironolactone, diuretic, enalapril, the patient showed 
clinical improvement and was discharged with the 
diagnosis of severe chagasic cardiomyopathy associated 
with decompensated heart failure profile B11.
In February 2018, a 24-hour ambulatory 
electrocardiogram (Holter) was performed, which showed 
a predominant sinus rhythm, with a minimum heart rate 
(HR) of 28 bpm, an average HR of 52 bpm, a maximum 
HR of 128 bpm and, complete right branch block. In this 
Holter, 8,648 episodes of pauses lasting 2.0 seconds or 
more were recorded due to sinus bradycardia, sinus pauses, 
sinoatrial block and junctional bradycardia, with the longest 
pause being 5.1 seconds. 8,400 supraventricular extra-
systoles were also observed, which are responsible for 
13% of beats, an unsustained supraventricular paroxysmal 
tachycardia and three ventricular extra-systoles, showing 
an arrhythmogenic component in heart disease and the use 
of beta-blockers as the cause of pauses, however, without 
indication of pacemaker implantation or defibrillator.
In November of the same year, the patient was 
again hospitalized, in sickbay area of the same hospital, 
with syncope and dyspnea, and she was not using the 
prescribed drugs (carvedilol, spironolactone, enalapril 
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and furosemide). An electrocardiogram was performed, 
showing a first-degree atrioventricular block, right branch 
block and left atrial overload (Figure 3). Holter was 
repeated with improved pauses, with an average HR of 
113 bpm. After stabilization, the patient was discharged 
from the hospital.
 
Figure 1. Echocardiogram: Ejection Fraction Measurement (Simpson method), Apical window Four Chamber. Ventricular ejection 
fraction: 23%
Figura 2. Deviation of Interventricular Septum into Left Ventricle due to pulmonary hypertension in diastole (D sign). Left parasternal 
window and short axis cut
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Legend: HR – Heart Rate
Figure 3. Electrocardiogram. Sinus rhythm, HR 74 bpm, first-degree atrioventricular block, complete right branch block and left atrial 
overload
In April 2019, the patient was again admitted to the 
Intensive Care Unit with severe asthenia associated with 
arterial hypotension, drop in oxygen saturation and atrial 
fibrillation with HR of 170 bpm with indeterminate onset 
time. Electrical cardioversion was performed, followed 
by infusion of intravenous amiodarone and need for 
inotropic (Dobutamine), developing with stabilization of 
the hemodynamic state. During hospitalization, the patient 
presented a third heart sound, systolic murmur, of intensity 
3 +/6+ in mitral focus, with inaudible blood pressure 
even with high doses of noradrenaline, jugular turgency 
and capillary filling time of 5 seconds. A chest x-ray was 
performed demonstrating an enlarged cardiac area, signs 
of pulmonary congestion, pleural effusion encysted on 
the right associated with alveolar veiling (Figure 4). She 
developed with changes in renal function and electrolytes, 
with progressive worsening of serum amount of urea, 
creatinine and, electrolytes, with hyperkalaemia, showing 
cardiorenal syndrome. After 72 hours, the patient died 
due to cardiogenic shock, with no possibility of renal 
replacement therapy, or other procedures, due to the 
severity of the evolution and hemodynamic instability.
Legend: CTI – Cardiothoracic Index
Figure 4. Chest x-ray. Enlarged cardiac area (CTI greater than 0.65 - cardiomegaly degree IV), signs of pulmonary congestion with 
cephalization of vascular network in the pulmonary apexes (green arrow), pleural effusion encysted on the right (red arrow), associated 
with alveolar veiling in the right base (yellow arrow)
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The diagnostic hypotheses raised during the 
last hospitalization were: decompensated heart failure, 
profile C of chagasic etiology, associated with treatment 
abandonment, cardiorenal syndrome, persistent atrial 
fibrillation with undetermined time and cardiogenic shock.
DISCUSSION
The natural history of Chagas disease comprises 
acute and chronic phases, with the chronic phase divided 
into indeterminate and determinate form. The indeterminate 
form, in general, is asymptomatic and lasts from 30 to 40 
years6, leading to symptoms in the sixth or seventh decade 
of life, when it becomes the determinate phase. However, 
according to Rassi, et al.9, the asymptomatic phase can 
last from 10 to 30 years and only 30 to 50% of patients 
in this phase will develop CCC, being the most frequent 
and the most severe of complications and representing the 
determinate chronic form.
Regarding the diagnosis of Chagas disease by 
serological criteria, the time between the onset of symptoms 
and the collection of blood sample must be taken into 
account, in addition to clinical and epidemiological 
evidences. When detecting immunoglobulin M (IgM), 
the diagnosis of acute condition is made and the title ≥ 
1:40 associated with IgG ≥ 1:80 should be considered as 
reagent. For confirmation by IgG marker, two collections 
are required with a minimum interval of 15 days between 
them, with the inclusion of the first and second samples in 
the same assay for comparative purposes10. In the diagnosis 
of chronic disease, it is necessary to combine two IgG 
tests that are reagent of different antigenic preparations 
or with different ways of achievements, which may be: 
ELISA (enzyme-linked immunosorbent assay), IFI (indirect 
immunofluorescence); HAI (indirect hemagglutination), 
WB (Western blot) or CLIA (chemiluminescence)10.
The Latin American Guideline for the Diagnosis 
and Treatment of Chagas Heart Disease shows the CCC 
classification and through the interpretation of such 
stages, the patient in the report was admitted to the first 
hospitalization, already in stage C with bi ventricular 
dysfunction (see echocardiogram and case description)6. 
In her last hospitalization, there was a significant increase 
in creatinine and urea, characterizing a “cardiorenal 
syndrome”, which can happen in up to 40% of patients with 
heart failure11. Due to the patient’s hemodynamic instability 
and rapid evolution of the case, it was not possible to 
perform alternative methods such as ultrafiltration and 
dialysis, recommended by the current guidelines in these 
cases.
Patient’s diagnostic research showed epidemiology 
and positive serology for T. Cruzi ,  suggestive 
electrocardiogram (see case description), echocardiogram 
with bi ventricular dysfunction, significant dilation of 
cardiac cavities and diffuse hypokinesia, which is more 
suggestive of Chagas heart disease than in others heart 
diseases12. In view of such cardiac manifestations and 
evolution, risk of death stratification for patients with CCC 
is an important tool/device in the prognosis, and can be 
assessed using Rassi Score (Table 1)9.
Table 1. Rassi Score to risk of death stratification in a patient 
with Chagas heart disease
Clinical feature Score
Male gender 2
ECG with low voltage QRS 2
Non-sustained ventricular tachycardia 3
Global change or segmental mobility of VE 3
Chest x-ray cardiomegaly 5
Heart failure CF III/IV NYHA 5
Sourde: Rassi et al.9
Based on this score, the patient had 13 points, 
representing a high risk of mortality (84 to 85%)12. The 
severity, recurrence and rapid progression of clinical 
manifestations presented by the patient would justify, in 
addition to the etiologic antiparasitic treatment, medication 
and non-medication for heart failure, the discussion of 
more specific and highly complex therapies, such as 
Cardiac Resynchronization Therapy (CRT) and heart 
transplantation.
With regard to etiological treatment of Chagas 
disease, the Clinical Protocol and Chagas Disease 
Therapeutic Guidelines10 suggest two main antiparasitic 
drugs for reducing the parasitic load on the body, which are 
Benznidazole and Nifurtimox. The most used in Brazilian 
context is Benznidazole, which, despite the indication in the 
acute phase, is not recommended for chronic disease that 
is in the advanced phase10. In the BENEFIT study, it was 
observed that antiparasitic treatment with Benznidazole 
in patients with CCC did not prove to be effective in 
improving the course of the disease and that, despite the 
negative serology for T. Cruzi, it did not show a decrease 
in mortality and clinical outcomes13.
In addition to antiparasitic medication treatment 
for Chagas disease, there are treatments for symptoms 
presented with the evolution of Chagas cardiomyopathy, 
which, in the case of this patient, predominated signs 
and symptoms of congestion and low cardiac output, 
requiring non medication treatment, based on water 
restriction, low sodium diet, vaccination against influenza 
and pneumococcus, physical exercise and drug treatment, 
mainly diuretics such as furosemide, angiotensin II-
converting enzyme antagonists, inhibitors of aldosterone 
receptors and beta-blockers14. Despite all these conducts 
been prescribed for the patient, seeking treatment for stage 
C heart failure of functional class IV11, following current 
guidelines, poor adherence to treatment made it impossible 
to assess therapeutic efficacy and reclassification to stage 
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D of Heart Failure.
Considering that CRT in CCC is a subject of intense 
discussion, it should be used predominantly in patients 
with optimized therapy and with left bundle branch block, 
characteristics not found in patient14. Heart transplantation 
represents the definitive therapy for treatment of HF, being 
also the treatment of choice for patients with end-stage 
Chagas disease cardiomyopathy8. However, the patient 
had exclusion criteria according to the 3rd Brazilian 
Cardiac Transplant Guideline15, since she presented severe 
psychiatric comorbidity, low social support, low adherence 
to treatment and it was unavailable in the service in which 
she was hospitalized, which despite being a tertiary 
hospital, had no qualification for heart transplantation, 
resynchronization or defibrillator implantation by Unified 
Health System (Sistema Único de Saúde - SUS) and, 
the transference of the patient for other services was not 
possible due to the severity of the condition.
Due to the limitations of heart transplantation 
in CCC, such as the restricted access of patients to this 
therapy, prolonged waiting time for transplantation and the 
chance of reactivation of Chagas disease in the context of 
immunosuppression, new studies seeking new options for 
therapeutic strategies have been conducted. Among such 
innovative strategies is bone marrow cell transplantation. 
The report of the first human experience about bone marrow 
cell transplantation performed in patients with heart failure 
caused by Chagas disease was made by Vilas-Boas et al.16 
and shows to be effective and viable. This cell therapy was 
performed by intracoronary injection of mononuclear cells 
from autologous bone marrow, it was considered safe and 
a 20% relative increase in left ventricular ejection fraction 
(LVEF) can be obtained in patients who had significantly 
decreased in it16. Although the therapy is promising, it still 
needs more studies and investments, it not being accessible 
in most hospitals.
It is important to emphasize, in this case, the early 
onset of symptoms in the fourth decade of life, unusual age 
range for the presentation of the determinate chronic form 
of Chagas cardiomyopathy. In addition, the severity and 
accelerated progression of signs and symptoms, leading 
to early death, draw attention and encourage us to seek 
treatments that can slow down the progression of this form 
of disease.
CONCLUSION
The presented report reveals disapproving clinical 
manifestations with rapid progression in young patient, 
such as heart failure, cardiogenic shock and cardiorenal 
syndrome, showing to have a worse prognosis and a high 
risk of mortality, according to Rassi Score. Early risk 
stratification is essential for a fast action in order to interrupt 
this accelerated evolution and control complications 
through appropriate therapeutic strategies, such as patient 
follow-up and monitoring, treatment of comorbidities 
and adherence to medication treatment, minimizing 
readmissions, in addition to directing ventricular support 
options and fast transference to a transplant center. There 
is also a need for further studies in young adult population 
in order to reduce morbidity and mortality in these cases, 
through therapies more accessible to the places where the 
disease is more prevalent.
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